These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23742289)

  • 1. proMetalloproteinase-10 is associated with brain damage and clinical outcome in acute ischemic stroke.
    Rodríguez JA; Sobrino T; Orbe J; Purroy A; Martínez-Vila E; Castillo J; Páramo JA
    J Thromb Haemost; 2013 Aug; 11(8):1464-73. PubMed ID: 23742289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High serum levels of endothelin-1 predict severe cerebral edema in patients with acute ischemic stroke treated with t-PA.
    Moldes O; Sobrino T; Millán M; Castellanos M; Pérez de la Ossa N; Leira R; Serena J; Vivancos J; Dávalos A; Castillo J
    Stroke; 2008 Jul; 39(7):2006-10. PubMed ID: 18436890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke: the Biomarker Evaluation for Antioxidant Therapies in Stroke (BEAT-Stroke) study.
    Kelly PJ; Morrow JD; Ning M; Koroshetz W; Lo EH; Terry E; Milne GL; Hubbard J; Lee H; Stevenson E; Lederer M; Furie KL
    Stroke; 2008 Jan; 39(1):100-4. PubMed ID: 18063832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prestroke Aspirin Use is Associated with Clinical Outcomes in Ischemic Stroke Patients with Atherothrombosis, Small Artery Disease, and Cardioembolic Stroke.
    Lin J; Han Z; Yi X; Luo H; Zhou Q; Zhou J
    J Atheroscler Thromb; 2019 Jun; 26(6):528-537. PubMed ID: 30429408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The importance of selected markers of inflammation and blood-brain barrier damage for short-term ischemic stroke prognosis.
    Lasek-Bal A; Jedrzejowska-Szypulka H; Student S; Warsz-Wianecka A; Zareba K; Puz P; Bal W; Pawletko K; Lewin-Kowalik J
    J Physiol Pharmacol; 2019 Apr; 70(2):. PubMed ID: 31356182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MMP9 variation after thrombolysis is associated with hemorrhagic transformation of lesion and death.
    Inzitari D; Giusti B; Nencini P; Gori AM; Nesi M; Palumbo V; Piccardi B; Armillis A; Pracucci G; Bono G; Bovi P; Consoli D; Guidotti M; Nucera A; Massaro F; Micieli G; Orlandi G; Perini F; Tassi R; Tola MR; Sessa M; Toni D; Abbate R;
    Stroke; 2013 Oct; 44(10):2901-3. PubMed ID: 23908067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased body iron stores are associated with poor outcome after thrombolytic treatment in acute stroke.
    Millan M; Sobrino T; Castellanos M; Nombela F; Arenillas JF; Riva E; Cristobo I; García MM; Vivancos J; Serena J; Moro MA; Castillo J; Dávalos A
    Stroke; 2007 Jan; 38(1):90-5. PubMed ID: 17138950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis.
    Lorente L; Martín MM; Labarta L; Díaz C; Solé-Violán J; Blanquer J; Orbe J; Rodríguez JA; Jiménez A; Borreguero-León JM; Belmonte F; Medina JC; Llimiñana MC; Ferrer-Agüero JM; Ferreres J; Mora ML; Lubillo S; Sánchez M; Barrios Y; Sierra A; Páramo JA
    Crit Care; 2009; 13(5):R158. PubMed ID: 19799791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke.
    Ning M; Furie KL; Koroshetz WJ; Lee H; Barron M; Lederer M; Wang X; Zhu M; Sorensen AG; Lo EH; Kelly PJ
    Neurology; 2006 May; 66(10):1550-5. PubMed ID: 16717217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke.
    Castellanos M; Leira R; Serena J; Blanco M; Pedraza S; Castillo J; Dávalos A
    Stroke; 2004 Jul; 35(7):1671-6. PubMed ID: 15166391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: a multicenter confirmatory study.
    Castellanos M; Sobrino T; Millán M; García M; Arenillas J; Nombela F; Brea D; Perez de la Ossa N; Serena J; Vivancos J; Castillo J; Dávalos A
    Stroke; 2007 Jun; 38(6):1855-9. PubMed ID: 17478737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
    Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S
    JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating CD133+CD34+ progenitor cells inversely correlate with soluble ICAM-1 in early ischemic stroke patients.
    Bogoslovsky T; Spatz M; Chaudhry A; Maric D; Luby M; Frank J; Warach S
    J Transl Med; 2011 Aug; 9():145. PubMed ID: 21871109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical and inflammatory biomarkers in ischemic stroke: translational study between humans and two experimental rat models.
    Martínez-Sánchez P; Gutiérrez-Fernández M; Fuentes B; Masjuán J; Cases MA; Novillo-López ME; Díez-Tejedor E;
    J Transl Med; 2014 Aug; 12():220. PubMed ID: 25086655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A higher body temperature is associated with haemorrhagic transformation in patients with acute stroke untreated with recombinant tissue-type plasminogen activator (rtPA).
    Leira R; Sobrino T; Blanco M; Campos F; Rodríguez-Yáñez M; Castellanos M; Moldes O; Millán M; Dávalos A; Castillo J
    Clin Sci (Lond); 2012 Feb; 122(3):113-9. PubMed ID: 21861843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study.
    Jauch EC; Lindsell C; Broderick J; Fagan SC; Tilley BC; Levine SR;
    Stroke; 2006 Oct; 37(10):2508-13. PubMed ID: 16960091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator.
    Ong CT; Wong YS; Wu CS; Su YH
    Drug Des Devel Ther; 2017; 11():1559-1566. PubMed ID: 28572721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia.
    Tsuji K; Aoki T; Tejima E; Arai K; Lee SR; Atochin DN; Huang PL; Wang X; Montaner J; Lo EH
    Stroke; 2005 Sep; 36(9):1954-9. PubMed ID: 16051896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of edaravone, a free radical scavenger, on circulating levels of MMP-9 and hemorrhagic transformation in patients with intravenous thrombolysis using low-dose alteplase.
    Tsuruoka A; Atsumi C; Mizukami H; Imai T; Hagiwara Y; Hasegawa Y
    J Stroke Cerebrovasc Dis; 2014; 23(10):2894-2899. PubMed ID: 25282183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of FLAIR hyperintense lesions as imaging biomarkers to predict the outcome of acute stroke after intra-arterial thrombolysis following intravenous tissue plasminogen activator.
    Chung JW; Kim KJ; Noh WY; Jang MS; Yang MH; Han MK; Kwon OK; Jung C; Kim JH; Oh CW; Lee JS; Lee J; Bae HJ
    Cerebrovasc Dis; 2013; 35(5):461-8. PubMed ID: 23735898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.